By Iain Gilbert
Date: Tuesday 18 Sep 2018
(Sharecast News) - Viking Therapeutics soared as much as 120% in early trading after the firm revealed a positive set of results from a mid-stage trial of its non-alcoholic fatty liver disease treatment.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 32.14 |
| Change Today | $ -3.28 |
| % Change | -9.26 % |
| 52 Week High | $42.89 |
| 52 Week Low | $21.28 |
| Volume | 8,275,559 |
| Shares Issued | 72.03m |
| Market Cap | $2,314.97m |
| RiskGrade | 326 |
| Strong Buy | 7 |
| Buy | 9 |
| Neutral | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 17 |

| Time | Volume / Share Price |
| 15:59 | 240 @ $32.13 |
| 15:59 | 100 @ $32.14 |
| 15:59 | 468 @ $32.14 |
| 15:59 | 100 @ $32.14 |
| 15:59 | 770 @ $32.11 |
You are here: research